Corbus Pharms. Holdi
Corbus Pharm holds a pipeline of oncology ADCs and anti‑integrin antibodies in early‑phase trials, plus a CB1 inverse agonist for obesity. With robust patent coverage and a Jenrin Discovery license, the company targets high‑potential markets for serious illnesses.
Headquarters: United States (USA)
- Website: Visit Site 🔗
- Type: Corporation
Company Profile
- Sector: Professional Services
- Industry: Biotechnology Research
- Employees: 28
- HQ: Norwood
Unlock the full potential.
Upgrade
Get access to Relative P/E Ratio Valuation Histogram.